Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: A case series

Clinical Infectious Diseases

Volumn 48, Issue 11, 2009, Pages

  Pepper, Dominique J ^a,b,c,i   Marais, Suzaan ^a,b   Maartens, Gary ^a,d   Rebe, Kevin ^a,c   Morroni, Chelsea ^b,e   Rangaka, Molebogeng X ^b,c,f   Oni, Tolu ^b,g   Wilkinson, Robert J ^a,b,c,g,h   Meintjes, Graeme ^a,b,c  

^a GF Jooste Hospital   (South Africa)

^b Institute of Infectious Disease and Molecular Medicine   (South Africa)

^c Department of Medicine ^*  (South Africa)

^d Division of Clinical Pharmacology   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

ⁱ GF Jooste Hospital   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LAMIVUDINE; NEVIRAPINE; OFLOXACIN; PLACEBO; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; STREPTOMYCIN; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CORTICOSTEROID;

ARTICLE; CASE STUDY; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRACRANIAL TUBERCULOMA; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MYELORADICULOPATHY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; TOXOPLASMOSIS; TUBERCULOMA; ADULT; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; TUBERCULOUS MENINGITIS;

ADRENAL CORTEX HORMONES; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; PROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOMA; TUBERCULOSIS, CENTRAL NERVOUS SYSTEM; TUBERCULOSIS, MENINGEAL; YOUNG ADULT;

EID: 66949164814     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598988     Document Type: Article

References (39)

1. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008;8:516-23.
2. Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and an-titubercular drug resistance. Clin Infect Dis 2009; 48:667-76.
3. Pepper DJ, Meintjes GA, Mcllleron H, Wilkinson RJ. Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Drug Discov Today 2007; 12:980-9.
4. Mcllleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol phar-macokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50:1170-7.
5. Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lynen L. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 2006; 10:946-53.
6. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006;57:167-70.
7. Fishman JE, Saraf-Lavi E, Narita M, Hollender ES, Ramsinghani R, Ashkin D. Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000; 174:43-9.
8. Buckingham SJ, Haddow LJ, Shaw PJ, Miller RF. Immune reconsti-tution inflammatory syndrome in HIV-infected patients with myco-bacterial infections starting highly active anti-retroviral therapy. Clin Radiol 2004; 59:505-13.
9. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11:1282-9.
10. Lee CH, Lui CC, Liu JW. Immune reconstitution syndrome in a patient with AIDS with paradoxically deteriorating brain tuberculoma. AIDS Patient Care STDS 2007;21:234-9.
11. Dautremer J, Pacanowski J, Girard PM, Lalande V, Sivignon F, Meynard JL. A new presentation of immune reconstitution inflammatory syndrome followed by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous meningitis. AIDS 2007; 21:381-2.
12. Sumner CJ, Newman M, Jay CA. Recurrent myelopathy after HAART in a patient with spinal mycobacterial infection. Neurology 2003;61:139-40.
13. Vidal JE, Cimerman S, Schiavon Nogueira R, et al. Paradoxical reaction during treatment of tuberculous brain abscess in a patient with AIDS. Rev Inst Med Trop Sao Paulo 2003;45:177-8.
14. Burch VC, Benatar SR. Rational planning for health care based on observed needs. S Afr Med J 2006; 96:796, 800, 802.
15. Harrison SNA. South African health review 2007. Durban: Health Systems Trust, 2007.
16. Results ofthe 2006 HIV-1 Antenatal Provincial and AreaSurveys. Cape Town: Western Cape Provincial Department of Health, 2007.
17. South African National Tuberculosis Control Programme Practical guidelines. Available at: http://wwwecdohgovza/uploads/files/150906152233 pdf . Accessed 29 November 2008.
18. South African Department of Health HIV-1 and AIDS. South African Department of Health HIV-1 and AIDS and STI strategic plan for South Africa 2007-2011. Available at: http://wwwdohgovza/docs/pol-icy/strat-plan/indexhtml. Accessed 29 November 2008.
19. World Health Organization. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents recommendations for HIV-1-prevalent and resource-constrained settings. Available at: http://whqlibdocwhoint/hq/ 2007/WHO-HTM-TB-2007379- engpdf. Accessed 29 November 2008.
20. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-24.
21. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl JMed 2004;351:1741-51.
22. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008:CD002244.
23. Lawn SD, Wood R. Hepatic involvement with tuberculosis-associated immune reconstitution disease. AIDS 2007; 21:2362-3.
24. Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006;4:469- 78.
25. Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr Opin HIV AIDS 2008; 3:438-45.
26. Bhigjee AI, Naidoo K, Patel VB, Govender D; Neuroscience AIDS Research Group. Intracranial mass lesions in HIV-positive patients: the KwaZulu/Natal experience. S Afr Med J 1999;89:1284-8.
27. Modi M, Mochan A, Modi G. Management of HIV-associated focal brain lesions in developing countries. QJM 2004;97:413-21.
28. Torre D, Casari S, Speranza F, et al; Italian Collaborative Study Group.Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother 1998;42:1346-9.
29. Thwaites GE, Lan NT, Dung NH, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005; 192:79-88.
30. Wasay M, Kheleani BA, Moolani MK, et al. Brain CT and MRI findings in 100 consecutive patients with intracranial tuberculoma. J Neuroim-aging 2003; 13:240-7.
31. Morgado C, Ruivo N. Imaging meningo-encephalic tuberculosis. Eur J Radiol 2005;55:188-92.
32. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157-61.
33. Kumarasamy N, Chaguturu S, Mayer KH, et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004;37:1574-6.
34. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gaz-zard BG. Clinical characteristics ofIRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005; 10:417-22.
35. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
36. Katrak SM, Shembalkar PK, Bijwe SR, Bhandarkar LD. The clinical, radiological and pathological profile of tuberculous meningitis in patients with and without human immunodeficiency virus infection. J Neurol Sci 2000; 181:118-26.
37. Thwaites GE, Duc Bang N, Huy Dung N, et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J Infect Dis 2005; 192:2134-41.
38. Torok ME, Chau TT, Mai PP, et al. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS ONE 2008;3:e1772.
39. Nicolato A, Gerosa M, Piovan E, et al. Computerized tomography and magnetic resonance guided stereotactic brain biopsy in nonimmuno-compromised and AIDS patients. Surg Neurol 1997;48:267-77.